AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,032.00GBp
6:17am EDT
Price Change (% chg)

72.00p (+1.82%)
Prev Close
3,960.00p
Open
4,000.00p
Day's High
4,060.00p
Day's Low
4,000.00p
Volume
2,165,353
Avg. Vol
2,628,175
52-wk High
4,147.07p
52-wk Low
3,028.50p

AZN.L

Chart for AZN.L

About

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes treatments... (more)

Overall

Beta: 0.34
Market Cap (Mil.): £49,852.54
Shares Outstanding (Mil.): 1,261.30
Dividend: 116.80
Yield (%): 4.45

Financials

  AZN.L Industry Sector
P/E (TTM): 32.57 32.71 32.86
EPS (TTM): 1.21 -- --
ROI: 6.49 19.60 18.86
ROE: 10.89 20.30 19.62
Search Stocks

UK's FTSE propped up by ABF and AstraZeneca

LONDON, April 23 - A rise in the share prices of Associated British Foods and drugmaker AstraZeneca buoyed Britain's top equity index on Wednesday, leaving the market near a two-week high.

3:38am EDT

Novartis and GSK trade assets as pharma industry reshapes

ZURICH/LONDON - Novartis and GlaxoSmithKline agreed to trade more than $20 billion worth of assets on Tuesday to bolster their best businesses and exit weaker ones as the drug industry contends with healthcare spending cuts and generic competition. | Video

22 Apr 2014

UPDATE 4-Novartis and GSK trade assets as pharma industry reshapes

* Deals, plus talk of Pfizer-Astra deal, lift sector shares (Adds details on Lilly animal health unit, updates share movement)

22 Apr 2014

M&A in pharmaceuticals helps European shares extend rally

* Indexes extend gains after strong consumer confidence data

22 Apr 2014

Deals and deal talk among pharmaceuticals lift Britain's FTSE

* FTSE 100 gains 0.9 pct * AstraZeneca surges on report of Pfizer approach * GlaxoSmithKline jumps on asset swap with Novartis (Updates with closing prices, adds technical detail) By Alistair Smout LONDON, April 22 - Corporate activity in the pharmaceutical sector on Tuesday pushed Britain's benchmark stock index to a two-week high and to within sight of a peak for this year. Drugmaker AstraZeneca rose 4.7 percent, with trading volumes in the stock more than three

22 Apr 2014

M&A activity in pharmaceuticals pushes UK's FTSE higher

* FTSE 100 up 1.1 pct * AstraZeneca surges on reported Pfizer bid interest * GlaxoSmithKline jumps on asset swap with Novartis (Adds detail, quote, updates prices) By Alistair Smout LONDON, April 22 - Merger and acquisition activity among drug companies drove Britain's top share index to a two-week high on Tuesday, putting it within sight of its peak for 2014. Drugmaker AstraZeneca surged 6.7 percent, with trading volumes in the stock over twice its 90-day average

22 Apr 2014

M&A in pharmaceuticals helps European shares extend rally

* Indexes extend gains after strong euro zone consumer confidence

22 Apr 2014

M&A activity in pharmaceuticals pushes UK's FTSE higher

* FTSE 100 up 1 pct * AstraZeneca surges on reported Pfizer bid interest * GlaxoSmithKline jumps on asset swap with Novartis (Adds detail, quote, updates prices) By Alistair Smout LONDON, April 22 - Merger and acquisition activity in the pharmaceutical sector drove Britain's top share index to a two-week high on Tuesday, putting it within sight of its peak for 2014. Drugmaker AstraZeneca surged 7.1 percent, with trading volumes in the stock nearly twice their 90-d

22 Apr 2014

M&A activity in pharma helps European stocks extend rally

LONDON\PARIS, April 22 - European shares rose on Tuesday, extending last week's gains, as mergers and acquisitions activity in the pharmaceuticals sector eclipsed disappointing results from Dutch conglomerate Philips.

22 Apr 2014

Novartis shake-up, Pfizer-AstraZeneca report lifts pharma stocks

LONDON, April 22 - Shares in European drugmakers received a shot in the arm on Tuesday amid a flurry of activity, with Novartis striking a multi-billion dollar deal with GlaxoSmithKline and reports U.S. giant Pfizer had approached Britain's AstraZeneca over a deal.

22 Apr 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Pechala's Reports
$15.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks